Categories
-
Adhesives
6
Amines
114
Amino Acids
199
Analytical Reagents
742
Antibiotics
263
Bioactive Small Molecules
780
Aroma Chemicals
238
Biochemicals
1116
Boronic Acids
4
Buffers
103
Building Blocks
2105
Carbohydrates
188
Catalysts
115
Chiral Compounds
74
Coccus nucifera oil
0
Detergents
60
Diagnostic Raw Materials
270
Flavours and Fragrance Materials
232
Fluorinated Products
57
Furans
7
Gases in Solution
51
Grignard Reagents
29
HPLC Reagents
8
Imidazoles
18
Indoles
46
Inorganic Chemicals
355
Ion-Pair Reagents
24
Ligands
80
Organics
1581
Oxazoles
3
Peptide Reagents
99
Phenols
52
Picolines
0
Piperazines
12
Pyrazines
3
Pyridines
62
Pyrimidines
34
Quaternary Ammonium salts
44
Reagents
111
Research Organics & Inorganics
859
Salts
308
Sealing Compounds
1
Sherclin
1
Solvents
131
Stains & Indicators
320
Sugars
65
Tailor-made solutions
1
Testing Standards
4
Uncategorised
29
Water Analysis
13
Escitalopram oxalate
(86905726 | 219861-08-2)
CAS: | 219861-08-2 |
---|---|
Molecular Formula: | C20H21FN2O · C2H2O4 |
Molecular Weight: | 414.43 |
Availablility: | In Stock |
---|---|
Downloads: | | |
86905726-1g | 1g | £176.20 | |
Bulk Order |
86905726-1g | 1g | €246.70 | |
Bulk Order |
86905726-1g | 1g | $264.30 | |
Bulk Order |
Safety Data Sheet
Certificate of Analysis
Product Detail
Product Code | 86905726 | ||||
Product Name | Escitalopram oxalate | ||||
Categories | Bioactive Small Molecules Research Organics & Inorganics | ||||
CAS | 219861-08-2 | ||||
Molecular Formula | C20H21FN2O · C2H2O4 | ||||
Molecular Weight | 414.43 | ||||
Storage Details | 2 to 8 °C | ||||
Harmonised Tariff Code | 2932990090 |
Product Specification
Melting Point | 148.5 - 152.5 ℃ | ||||
Specific rotation | +12 to +13.5 | ||||
Heavy metals | ≤10ppm | ||||
pH | 2.0 - 4.0 | ||||
Loss on Drying | ≤0.5% | ||||
Assay | ≥99.0% | ||||
Residue on Ignition | ≤0.1% | ||||
Individual impurity | ≤0.2% | ||||
Total Impurities | ≤0.5% | ||||
Appearance | White crystalline powder |
Safety Information
Pictograms |
|
||||
Signal word | warning | ||||
Hazard statements |
|
||||
Precautionary statements |
|